12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
We’ve previously written about how appraisal rights are a factor considered by deal-makers during t...
Read More >
The Employee Benefits Practice is pleased to present the Employee Benefits Developments Newsletter f...
Read More >
Much has already been written regarding the potential of COVID-19 to impact construction or developm...
Read More >
On July 1, the US Department of Education released a final rule that rescinds the entirety of the Ob...
Read More >
On June 14, 2019, the Southern District of New York declined to certify a consumer fraud class actio...
Read More >
While the gig economy often gets derided by worker advocates for being unfair to its workers, one as...
Read More >